Daesung Microbiological Labs Balance Sheet Health
Financial Health criteria checks 3/6
Daesung Microbiological Labs has a total shareholder equity of ₩37.3B and total debt of ₩23.8B, which brings its debt-to-equity ratio to 63.8%. Its total assets and total liabilities are ₩64.3B and ₩26.9B respectively.
Key information
63.8%
Debt to equity ratio
₩23.82b
Debt
| Interest coverage ratio | n/a |
| Cash | ₩11.73b |
| Equity | ₩37.35b |
| Total liabilities | ₩26.94b |
| Total assets | ₩64.29b |
Recent financial health updates
Is Daesung Microbiological Labs (KOSDAQ:036480) Using Too Much Debt?
May 08
Is Daesung Microbiological Labs (KOSDAQ:036480) A Risky Investment?
Jan 21
Recent updates
Is Daesung Microbiological Labs (KOSDAQ:036480) Using Too Much Debt?
May 08Is The Market Rewarding Daesung Microbiological Labs. Co., Ltd. (KOSDAQ:036480) With A Negative Sentiment As A Result Of Its Mixed Fundamentals?
Mar 15We're Not Counting On Daesung Microbiological Labs (KOSDAQ:036480) To Sustain Its Statutory Profitability
Feb 17Is Daesung Microbiological Labs (KOSDAQ:036480) A Risky Investment?
Jan 21Update: Daesung Microbiological Labs (KOSDAQ:036480) Stock Gained 83% In The Last Five Years
Dec 31Daesung Microbiological Labs. Co., Ltd. (KOSDAQ:036480) Is Up But Financials Look Inconsistent: Which Way Is The Stock Headed?
Dec 10Here's Why We Don't Think Daesung Microbiological Labs's (KOSDAQ:036480) Statutory Earnings Reflect Its Underlying Earnings Potential
Nov 19Financial Position Analysis
Short Term Liabilities: A036480's short term assets (₩28.7B) exceed its short term liabilities (₩10.4B).
Long Term Liabilities: A036480's short term assets (₩28.7B) exceed its long term liabilities (₩16.5B).
Debt to Equity History and Analysis
Debt Level: A036480's net debt to equity ratio (32.4%) is considered satisfactory.
Reducing Debt: A036480's debt to equity ratio has increased from 2.5% to 63.8% over the past 5 years.
Debt Coverage: A036480's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: Insufficient data to determine if A036480's interest payments on its debt are well covered by EBIT.